Brian Nowosielski

From PBM reform designed to benefit pharmacies to closures impacting the greater public health sector, Tom DePietro, PharmD, discusses current developments in community pharmacy.

Despite a myriad of data and news releases about the growing prominence of AI in pharmacy practice, several knowledge and acceptance gaps persist.

An exploration of key takeaways from the first 4 episodes of Scripted for Her, featuring host Natalie DiPietro Mager, PharmD, PhD, and experts from a variety of clinical backgrounds in women’s health.

As diabetes rises to be one of the most prominent chronic diseases globally, pharmacists have reached out as key resources for preventing and managing its complications.

As health officials respond to ongoing concerns, Nathan Ott, PharmD, joined to discuss key hantavirus facts that pharmacists can relay to their communities.

Among both childhood and adult populations, researchers assess the quality of life across a large cohort of patients reporting pneumococcal disease cases.

In part 2, Staci-Marie Norman, PharmD, CDCES, FAPhA, and Susan Cornell, PharmD, CDCES, FAPhA, FADCES, discuss the pharmacist’s ability to meander a booming medication class in GLP-1s.

Despite common trends in the specialty drug market persisting, a new pharmacy landscape must come together to address rising issues.

Preventing pneumococcal disease remains a cornerstone of public health, yet the strategy for protection is increasingly individualized and complex.

This episode explores the differences between behavior that is caught rather than taught, explaining how leadership can be a learned skill if properly approached.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES, and Staci-Marie Norman, PharmD, CDCES, FAPhA, discuss current trends regarding CGM use and access behind the pharmacy counter.

Researchers explore invasive pneumococcal disease epidemiology after the introduction of multiple pneumococcal conjugate vaccines.

The weight-loss and diabetes drug will now be available via Amazon Pharmacy for same-day delivery or in-person kiosk pickup.

As artificial intelligence becomes commonplace in medical practice, officials are gradually uncovering significant safety risks.

With value-based care initiatives on the rise in the US health care system, one partnership in Ohio is showing early signs of significant success.

Exploring data across a variety of income settings, researchers conduct a review of invasive pneumococcal disease carriage, cases, and their associations.

Episode 10 explores recent guideline changes in clinicians’ management of dyslipidemia, highlighting much more than a few updated recommendations.

In part 2, Kevin Day, PharmD, breaks down the Pharmacy Quality Rewards Program and its push toward value-based care in pharmacy practice.

Exploring clinical prioritization and macroeconomic investment, researchers examine the link between disease and economic burden of diabetes.

With continued pressure for federal action regarding the abortion drug mifepristone, SCOTUS blocked a previous decision that would limit the pill’s access.

Despite WHO officials stating that risks from the outbreak remain low, experts are acting urgently to uncover details and provide support.

Kevin Day, PharmD, provides insight into his role in the Pharmacist Quality Rewards Program and what it’s doing for patients in his community.

Utilizing colleges and schools of pharmacy, researchers explorensolutions to the growing challenges affecting community pharmacy.

Among community pharmacies and their patients, researchers explore the power of protected learning time for improving services and outcomes.

With its capabilities improving rapidly in the health care space, technology and pharmacy experts discuss AI’s future place in pharmacy practice as further developments are released.

Amid shifting vaccine recommendations and an evolving health care landscape, pharmacists continue to weather the storm as frontline community immunizers.

An exploration of community pharmacists’ perceptions of e-pharmacy, assessing whether they believe it’s a threat or benefit.

In adult patients at least 50 years old, researchers estimated lifetime costs and health outcomes of the 23-valent pneumococcal polysaccharide vaccine.

In part 2 of our World Immunization Week interview with Nathan Ott, PharmD, he discusses the power of collaboration and continuing education in boosting vaccine awareness.

In this episode, host Taylor Watterson, PharmD, PhD, brings us a solo rendition breaking down some of her recent research with SCRPTS Laboratory.